• E-mail :[email]
  • Phone : +33 4 69 16 66 69
  • Location : Lyon, France
Last update 2023-01-16 10:46:53.579

Philippe Bertolino PhD, HDR

Course and current status


  • Current position

- INSERM staff Scientist (CR), Cancer Research Centre of Lyon (CRCL), U1052, Univ. Lyon I. 

- Co-head of the: “Tumour Environment & Pituitary Oncology” group.


  • Scientific career

- From 2016: Co-head of the: “Tumour Environment & Pituitary Oncology” group.

- 2012-2013: Member of the Executive board of the CRCL, U1052, Lyon  

- 2010-2015: Staff Scientist – Team Endocrine Tumours, CRCL, U1052, Lyon             

- 2008-2009: Staff Scientist -  Karolinska Institute, Stockholm (Sweden). CF Ibanez’ Lab

- 2004-2008: Postdoc Fellow -  Karolinska Institute, Stockholm (Sweden). CF Ibanez’ Lab

- 2003-2004: Postdoc Fellow -  Netherlands Cancer Institute (NKI), Amsterdam (NL). P Ten Dijke’ lab


  • Academic responsibilities

- From 2016: Administrative board of the Société Française d’endocrinologie (SFE).

- From 2010: Member of the steering committee of the animal facility ANICAN, CRCL.

- From 2012: Member of CECCAPP evaluation board (Lyon’ Animal experimentation ethical commitee).

- From 2011: Member of the European Association for the Study of Diabetes (EASD)


  • Awards

- 2016: Prix PFIZER-SFE de Recherche en Endocrinologie

- 2008: Vetenskaprådet starting grant, Assistant Professorship at Karolinska Institute (Sweden)

- 2004-2006:Wenner-Gren Stiftelserna (Sweden)

- 1999-2003: PhD MRT fellow (France, Ministère de la Recherche et des Technologies)

Scientific summary

Philippe Bertolino is currently employed at the - Cancer Research Centre of Lyon/CRCL, since January 2016, holding the title of Head of the Tumour Environment & Pituitary Oncology team. He is also currently employed at Institut National de la Santé et de la Recherche Médicale, since November 2009, holding the title of Chargé de recherche. From October 2004 - February 2009, he held the position of Scientific Researcher, at Karolinska Institutet (Sweden) working on the identification of new therapeutic target for type 2 diabetes and obesity. Previously, He held a position of Postdoctoral Researcher at Netherlands Cancer Institute (NKI/AvL, the Netherlands). Philippe got his PhD while working at the WHO (France) working on the development of preclinical model for endocrine tumors. He got Doctor in Biology in Molecular Biology and has the habilitation to direct researches from the Université de Lyon. Our team aims at studying, modelling and developping new therapeutics to target endocrine tumors.

Over the last decade, we pointed the trans-differentiation and cell plasticity mechanism that exist in pancreatic tumors (Lu et al, Gastroenterology 2010; Ripoche et al, Mol Cell Biol. 2015, Zhao et al, Cancer Res 2020). Our work has shown the role of the TGFbi matrix protein as an immune remodeler and a potent target in type 2 diabetes and pancreatic cancers (Patry et al, Diabetes 2015; Goehrig et al, Gut 2019)

Since 2016, PB’ team is actively investigating the mechanisms that drive Pituitary neuroendocrine tumors. Our expertise in the field is acknowledged by a large number of publications that cover clinical reports to fundamental research involving omics, evaluation of therapeutic targets, studies on pituitary tumors microenvironment and human PDX manipulation (Raverot et al, JCEM 2017; Lasolle et al, Eur J Endocrinol 2017; Ilie et al Cancers 2019; Principe et al, JCEM 2020; Lasolle et al, Acta Neuropathol Com 2020; ; Ile et al, Cancers 2020).

The team is also one of the 45 members of the international Visium Clinical Translational Research Network (CTRN, 10xGenomics) whose research aim at developing single cell transcriptomics and Visium spatial transcriptomic to address clinical needs.

Using single-cell, spatial transcriptomics (scRNAseq, Visium), patient-derived xenografts (PDX) and primary culture of tumor-derived organoids, we are currently exploring the histological, genetic and signaling landscape of those tumors at the single cell resolution. Our major interest aims at identifying therapeutic candidates that will target the exchanges that exist between tumor cells and their microenvironment.



Image d’exemple